William Blair Issues Pessimistic Forecast for BDX Earnings

Becton, Dickinson and Company (NYSE:BDX) – Analysts at William Blair lowered their Q1 2025 EPS estimates for shares of Becton, Dickinson and Company in a research note issued on Friday, November 8th. William Blair analyst A. Brackmann now expects that the medical instruments supplier will earn $3.13 per share for the quarter, down from their prior estimate of $3.17. The consensus estimate for Becton, Dickinson and Company’s current full-year earnings is $13.11 per share. William Blair also issued estimates for Becton, Dickinson and Company’s Q2 2025 earnings at $3.50 EPS, Q3 2025 earnings at $3.73 EPS, Q4 2025 earnings at $4.01 EPS and FY2025 earnings at $14.37 EPS.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.77 by $0.04. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The company had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. During the same quarter in the prior year, the company posted $3.42 EPS. The business’s revenue was up 6.9% on a year-over-year basis.

Several other equities research analysts have also weighed in on BDX. Evercore ISI upped their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Stifel Nicolaus upped their target price on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a report on Friday, July 26th. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their target price for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. Finally, Raymond James lowered their target price on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of “Buy” and an average target price of $283.00.

Becton, Dickinson and Company Trading Up 2.0 %

Shares of BDX stock opened at $231.64 on Monday. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $249.89. The stock has a market cap of $66.95 billion, a price-to-earnings ratio of 47.66, a P/E/G ratio of 1.80 and a beta of 0.43. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.36 and a current ratio of 1.85. The firm has a fifty day moving average of $237.04 and a 200-day moving average of $235.09.

Institutional Investors Weigh In On Becton, Dickinson and Company

A number of hedge funds have recently added to or reduced their stakes in BDX. John G Ullman & Associates Inc. acquired a new position in Becton, Dickinson and Company during the 3rd quarter valued at about $270,000. Landscape Capital Management L.L.C. acquired a new position in Becton, Dickinson and Company during the 3rd quarter valued at about $461,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its position in Becton, Dickinson and Company by 79.0% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 317,422 shares of the medical instruments supplier’s stock valued at $76,530,000 after purchasing an additional 140,051 shares during the period. Cornerstone Advisors LLC lifted its position in Becton, Dickinson and Company by 11.1% during the 3rd quarter. Cornerstone Advisors LLC now owns 7,000 shares of the medical instruments supplier’s stock valued at $1,688,000 after purchasing an additional 700 shares during the period. Finally, Citizens Financial Group Inc. RI lifted its position in Becton, Dickinson and Company by 4.1% during the 3rd quarter. Citizens Financial Group Inc. RI now owns 3,942 shares of the medical instruments supplier’s stock valued at $950,000 after purchasing an additional 157 shares during the period. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th will be issued a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, December 9th. This represents a $4.16 dividend on an annualized basis and a yield of 1.80%. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. Becton, Dickinson and Company’s dividend payout ratio is currently 78.19%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.